Dr. Berlin received his doctorate in biostatistics from the Harvard School of Public Health in 1988. After spending 15 years as a faculty member at the University of Pennsylvania, in the Center for Clinical Epidemiology and Biostatistics, Jesse left Penn to join Janssen Research & Development in Biostatistics. He now serves as Vice President and Global Head of Epidemiology across Johnson & Johnson, responsible for pharmaceuticals, devices and consumer products. He has coauthored over 270 peer-reviewed publications in a variety of clinical and methodological areas, including papers on the study of meta-analytic methods for both randomized trials and epidemiology. He served on an Institute of Medicine Committee that developed recommendations for the use of systematic reviews in clinical effectiveness research, and served as Chair of the Scientific Advisory Committee to IMEDS (Innovation in Medical Evidence Development and Surveillance), part of the Reagan-Udall Foundation. Dr. Berlin co-chairs the Scientific Oversight Committee (with Greg Pappas from FDA) for MDEpiNet, a public-private partnership which is working toward developing methods and data sources for the evaluation of medical devices. Dr. Berlin served as an editorial team member of working group X for CIOMS (The Council for International Organizations of Medical Sciences), which has published guidelines for meta-analysis of drug safety data in the regulatory context. He was elected as a fellow of the American Statistical Association in 2004. In 2013, Dr. Berlin received the Lagakos Distinguished Alumni Award from the Department of Biostatistics at the Harvard School of Public Health.
- Amy P. Abernethy, US FDA
- Graeme Archer, GSK R&D
- Jesse Berlin, Johnson & Johnson
- Lawrence Carin, Duke
- Noémie Elhadad, Columbia
- Igor Jurisica, Krembil Research Institute and University of Toronto
- Faisal Khan, AstraZeneca
- Kannan Natarajan, Pfizer
- Amol Navathe, University of Pennsylvania
- Adler Perotte, Columbia
- Patrick Ryan, Janssen Research and Development
- Mary Ann Slack, US Food and Drug Administration (FDA)
- Simon Tavaré, Columbia
- Mihaela van der Schaar, Cambridge
- Li Wang, AbbVie
Countdown to AIPM
AIPM has begun!
Welcome Address — David Madigan, Ph.D., Columbia University
A Perspective on the Promise and Pitfalls of Artificial Intelligence in Clinical Drug Development — Kannan Natarajan, Pfizer Inc.
Machine Learning: Changing the future of healthcare – from next generation clinical trials to individualized treatment effects — Mihaela van der Schaar, University of Cambridge
Discussant — Patrick Ryan, Janssen Research and Development
ML and AI in Clinical Development and Statistical Innovation — Wang Li, AbbVie.
Opportunities for AI in Healthcare — Lawrence Carin, Duke University
- Demissie Alemayehu, Pfizer Inc.
- David Madigan, Columbia University